Orion Oyj (OTCMKTS:ORINY - Get Free Report)'s stock price dropped 0.9% during mid-day trading on Tuesday . The company traded as low as $23.36 and last traded at $23.36. Approximately 151 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 488 shares. The stock had previously closed at $23.57.
Orion Oyj Stock Performance
The firm's 50 day moving average is $25.51 and its 200 day moving average is $23.68. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.29 and a current ratio of 2.39. The stock has a market cap of $6.59 billion, a P/E ratio of 18.54 and a beta of 0.22.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $0.63 EPS for the quarter. Orion Oyj had a return on equity of 41.41% and a net margin of 23.01%. The firm had revenue of $517.97 million for the quarter. Analysts anticipate that Orion Oyj will post 1.26 EPS for the current year.
Orion Oyj Cuts Dividend
The company also recently disclosed a dividend, which was paid on Thursday, November 7th. Stockholders of record on Wednesday, October 16th were paid a dividend of $0.2405 per share. The ex-dividend date of this dividend was Wednesday, October 16th. Orion Oyj's payout ratio is 26.98%.
About Orion Oyj
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Featured Stories
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
